Groundwater Development in Arid Basins

Summary: Groundwater development frequently provides a means whereby tremendous new economic opportunities are opened up. If supplies are overdrawn (mined) the ensuing regional economy may be able to affort replacements from more costly sources. In the United States the Salt River Valley of Arizona and the valleys of California provide examples. Two cases are treated in this paper, Israel and West Pakistan. In Israel, besides furnishing more than half of the basic source of water suppply, groundwater development provides opportunity for both quantity and quality management, which makes possible use of surface supplies and reclaimed sewage as firm rather than marginal sources. This development will permit the total water resources of this small country, where agricultural production ranks among the world\u27s most efficient, to be utilized effectively down to almost the last drop by the mid 1970\u27s. Israel must then look to desalted water from the sea for further expansion of its overall water supply. In West Pakistan a combination of level terrain and leaky canals since about 1890 led to threatened waterlogging and salinity of more than 25 million acreas of irrigated land, even though supplies were less than half adequate for good productivity. By the 1950\u27s low yields and increasing population threatened starvation. However, initiation of groundwater development, first by the government and later by pricate entreprise, has, since 1960, let to construction of 3,500 governmental tube wells of about 3 cfs capacity and 30,000 private tube wells of slightly less than 1 cfs capacity. Results have been dramatic. Agricultural production and use of fertilizer are rapidly increasing, and opening of well development of pricate enterprise is providing the irrigator with benefits of free competition for his water custom which he did not previously enjoy. Ultimately, besides providing full supplies for an estimated 26 to 30 million acrea, drainage and salinity problems will be mitigated if about 50 million acre-feet are pumped each year from groundwater including about 28 million acre-feet to be mined from a reserve of about 1,900 million acre-feet. With some difficult surface storage development due to terrain, mining may eventually be reduced. Through an eventual technological solution for the continuing overdraft is not now in sight, perhaps an economy may be built which can affort such a solution when the time comes

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Lower Bulloch Dam Site Analysis and Cost Estimates

Statistics, graphs, and correspondence relating to Lower Bulloch Dam project to provide hydropower to Cedar Cit

Effect of rituximab on human in vivo antibody immune responses

BACKGROUND: B-lymphocyte depletion with rituximab has been shown to benefit patients with various autoimmune diseases. We have previously demonstrated that this benefit is also apparent in patients with newly diagnosed type 1 diabetes. OBJECTIVES: The effect of rituximab on in vivo antibody responses, particularly during the period of B-lymphocyte depletion, is incompletely determined. This study was designed to assess this knowledge void. METHODS: In patients with recent-onset type 1 diabetes treated with rituximab (n = 46) or placebo (n = 29), antibody responses to neoantigen phiX174 during B-lymphocyte depletion and with hepatitis A (as a second neoantigen) and tetanus/diphtheria (as recall antigens) after B-lymphocyte recovery were studied. Anti- tetanus, diphtheria, mumps, measles, and rubella titers were measured before and after treatment by means of ELISA. Antibody titers and percentage IgM versus percentage IgG to phiX174 were measured by means of phage neutralization. B-lymphocyte subsets were determined by means of flow cytometry. RESULTS: No change occurred in preexisting antibody titers. Tetanus/diphtheria and hepatitis A immunization responses were protective in the rituximab-treated subjects, although significantly blunted compared with those seen in the controls subjects, when immunized at the time of B-lymphocyte recovery. Anti-phiX174 responses were severely reduced during the period of B-lymphocyte depletion, but with B-lymphocyte recovery, anti-phiX174 responses were within the normal range. CONCLUSIONS: During the time of B-lymphocyte depletion, rituximab recipients had a decreased antibody response to neoantigens and significantly lower titers after recall immunization with diphtheria and tetanus toxoid. With recovery, immune responses return toward normal. Immunization during the time of B-lymphocyte depletion, although ineffective, does not preclude a subsequent response to the antigen